Comparison of Two Molecular Methods for Rapid Diagnosis of Extrapulmonary Tuberculosis by Causse, Manuel et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2011, p. 3065–3067 Vol. 49, No. 8
0095-1137/11/$12.00 doi:10.1128/JCM.00491-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Comparison of Two Molecular Methods for Rapid
Diagnosis of Extrapulmonary Tuberculosis
Manuel Causse,1 Pilar Ruiz,2 Juan Bautista Gutiérrez-Aroca,1,2 and Manuel Casal1,2*
Microbiology Service, Reina Sofia University Hospital,1 and Mycobacteria Reference Center, Microbiology Department,
Faculty of Medicine, University of Cordoba,2 Córdoba, Spain
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Application of real-time PCR for the detection of Mycobacterium tuberculosis enables results to be obtained
in about 2 h. A total of 340 nonrespiratory samples were processed using two real-time PCR assay kits: Xpert
MTB/RIF and Cobas TaqMan MTB. The sensitivity and specificity of the Xpert assay were 95% and 100%,
respectively, compared to 78% and 98% for the Cobas assay.
Mycobacterium tuberculosis is a major public health concern.
Because the bacterium spreads from person to person, effec-
tive and, above all, rapid diagnosis is a key objective of world-
wide tuberculosis control strategies.
Conventional M. tuberculosis detection techniques, based
on microscopic examination of Ziehl-Neelsen or auramine-
stained specimens, are still in widespread use for diagnostic
purposes, even though they fail to provide the required sensi-
tivity and specificity.
Since the discovery of the PCR in the mid-1980s, a number
of molecular techniques have been developed which yield a
high degree of sensitivity and, above all, specificity for M.
tuberculosis.
Although various supports have been tested both for direct
specimen-based detection and for identification on culture me-
dia, growth in a solid or liquid medium is still considered the
reference method for the diagnosis of M. tuberculosis infection.
In 2009, nevertheless, the Centers for Disease Control and
Prevention recommended the use of at least one molecular
technique per patient for M. tuberculosis detection (5).
One of the molecular techniques most widely used for the
detection of M. tuberculosis in respiratory samples is the com-
mercial PCR kit Cobas Amplicor MTB (Roche Diagnostics,
Indianapolis, IN), which has been available since the 1990s (4,
7). Problems have been reported using this kit, particularly
with nonrespiratory samples, due to the presence of inhibitor
enzymes and contamination (9). Even so, this is still generally
considered the molecular reference technique (11, 15).
Although the development of real-time PCR assays has im-
proved the speeds, sensitivities, and specificities of these mo-
lecular techniques, the new real-time methods have still not
been widely adopted. A number of noncommercial techniques
are available for M. tuberculosis detection (6, 14).
Cobas TaqMan MTB (Roche Molecular Systems, Branch-
burg, NJ) is a real-time PCR-based kit using TaqMan hydro-
lysis probes and primers that bind to a specific, highly con-
served region of the Mycobacterium genome containing the
gene for 16S rRNA. Specimens are prepared manually for the
extraction of M. tuberculosis DNA, and the TaqMan kit is then
used for amplification and detection in batches of 10 samples
with two controls, in order to optimize reagent use. This tech-
nique is routinely used in modern molecular microbiology lab-
oratories for the diagnosis of tuberculosis in respiratory spec-
imens.
The new Xpert MTB/RIF (Cepheid AB, Bromma, Sweden)
assay technique is based on heminested PCR technology and
uses 5 molecular probes to confirm M. tuberculosis detection;
the assay targets the rpoB gene of wild-type M. tuberculosis
strains. The real-time PCR assay consists of a single-use mul-
tichambered cartridge preloaded with the buffers and reagents
required for sample processing, amplification, and detection. A
barcode on each cartridge enables test details to be completed
automatically by the software.
This paper reports on a comparison of these two widely used
and intensively marketed real-time PCR test kits for the de-
tection of M. tuberculosis in extrapulmonary samples, using a
standard culture system as the reference method.
A total of 340 consecutive extrapulmonary samples were
taken from 289 patients ages 5 to 83 years (mean, 45) between
May 2009 and December 2010; males outnumbered females
(63.8% versus 30.9%). Sample sources were as follows: 50
cerebrospinal fluid (CSF) samples, 34 pleural fluid samples, 58
articular fluid samples, 20 ascitic fluid samples, 98 biopsy spec-
imens (80 lymph node, 10 lung, 4 stomach, and 4 bone sam-
ples), 54 gastric aspirates, 12 pericardial fluid samples, and 14
purulent exudates.
Samples deemed nonsterile (all except CSF and pleural
fluid) were decontaminated using the N-acetyl-L-cysteine–so-
dium hydroxide (NALC-NaOH) method. All samples were
then centrifuged for 20 min at 3,000 rpm, stained with aura-
mine, and visualized by fluorescent microscopy. They were
then inoculated into pyruvate-enriched Lowenstein-Jensen
medium and Middlebrook 7H9 broth.
Decontaminated samples were used for the manual extrac-
tion of M. tuberculosis DNA, as required by the Cobas TaqMan
MTB assay protocol, and for the preparation of samples using
the Xpert MTB/RIF assay kit.
DNA extractions were prepared using the Amplicor respi-
ratory specimen preparation kit, adding 500 l of wash solu-
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tion to 100 l of sample. The mixture was shaken and then
centrifuged at 12,500  g for 10 min. The supernatant was
aspirated with a fine-tip pipette, and 100 l of lysis reagent was
added to the pellet. Tubes were vortexed for 5 s, incubated in a
dry-heat block at 60°C for 45 min, pulse centrifuged for 5 s, and
neutralized by the addition of 100 l of neutralizing reagent;
finally, tubes were shaken for a further 5 s. Sample eluate was
used for the real-time PCR Cobas TaqMan MTB assay (in a
TaqMan 48 analyzer) once the appropriate master mix had
been prepared. The positive and negative controls supplied
with the two kits were used.
For the Xpert MTB/RIF test, 1 ml of decontaminated sam-
ple was diluted in 2 ml of the sample buffer included in the
assay kit. The solution was vortexed for 15 s and then left to
settle for 15 min, with vortexing for 15 s halfway through. A
specific volume was collected using the calibrated pipette sup-
plied with the kit and transferred to the cartridge. The software
was then programmed, and the cartridge was inserted in the
GeneXpert instrument.
The results obtained using these two assay protocols were
compared with those of cultures in solid and liquid media and
with acid-fast bacillus (AFB) smear results.
Statistical analysis was carried out using EpiInfo version
6.04d.
The culture method was used for reference purposes. AFB
smear-positive, culture-negative samples were deemed to be
culture positive, for statistical purposes, wherever chart review
indicated that a patient with earlier culture-positive specimens
had become culture negative following anti-TB (tuberculosis)
drug therapy, since PCR assays can detect nonviable mycobac-
teria.
Of the 340 samples, 41 grew in solid or liquid medium,
taking a median time of 14 days. Of these, 39 were identified as
positive by Xpert MTB/RIF (the two false negatives—one CSF
specimen and one biopsy specimen—were both AFB smear
negative). Thirty-two of the 41 were identified as positive using
the Cobas TaqMan MTB assay kit. The nine false negatives (3
biopsy specimens, 2 CSF specimens, 2 gastric aspirates, 1 pu-
rulent exudate, and 1 pleural fluid specimen) were all AFB
smear negative.
The culture-positive specimens included 18 biopsy speci-
mens (16 lymph node and 2 bronchial), 6 cerebrospinal fluid
specimens (2 from the same patient), 8 gastric aspirates, 4
pleural fluid specimens, and 5 purulent exudates. AFB smear
results were negative in 38 cases and positive in 3 cases.
For the 299 culture-negative samples, Xpert MTB/RIF
yielded no positive PCR result, while the Cobas TaqMan MTB
assay identified 5 culture-negative specimens as PCR positive
(2 biopsy specimens, 1 gastric aspirate, 1 CSF fluid sample, and
1 pleural fluid sample). These possible false positives were
attributed to PCR contamination, since there was no sign of M.
tuberculosis infection in the other specimens from these pa-
tients tested using conventional TB detection techniques. In-
stitutional review board (IRB) approval was granted for a chart
review, including all five apparently false-positive cases: none
of the patients concerned had received anti-TB therapy, and
none exhibited signs or symptoms suggestive of tuberculosis.
The findings were thus classed as false positives.
Sensitivity and specificity were 95% and 100%, respectively,
for the Xpert MTB/RIF assay kit, compared with 78% and
98% for the Cobas TaqMan MTB kit. Positive predictive val-
ues (PPV) and negative predictive values (NPV) were 100%
and 99%, respectively, for the Xpert MTB/RIF kit, compared
with 86% and 97% for the Cobas TaqMan MTB kit.
A 79.9% match was achieved between the two molecular
techniques, with a kappa index of 0.8 (95% confidence interval
[CI] of 0.7 to 0.9).
Statistical data for performance are shown in Table 1.
Xpert MTB/RIF appears to be as effective in nonrespiratory
samples as it has proved to be in preliminary studies using
respiratory samples (2, 3, 10). Results for sensitivity were sim-
ilar to those reported elsewhere (ranging from 90% in AB
smear-negative samples to 99% in AFB smear-positive speci-
mens; overall sensitivity, 97%). Findings for specificity (98%)
were also similar to those reported by other authors (2, 3, 10).
Specificity and negative predictive values were similar to
those recorded for other molecular techniques used in non-
respiratory samples, while sensitivity and positive predictive
values in our study were considerably better than the 57% and
78%, respectively, reported for the Cobas Amplicor MTB test
in nonrespiratory samples (12) and closer to the 83 to 88%
sensitivity reported for the GenProbe amplified M. tuberculosis
direct (AMTD) assay, also in extrapulmonary samples (1, 8).
In general terms, the Xpert/MTB assay performed better
than the Cobas TaqMan MTB; sensitivity, in particular, was
substantially greater (87 to 100% versus 64 to 91%). Statistical
performance data reported elsewhere for the Cobas TaqMan
MTB assay are similar to those indicated here: sensitivity of 79
to 91%, specificity of 98%, PPV of 73%, and NPV of 98% (13).
The high sensitivity recorded for the Xpert MTB test in the
present study (95%) may be due to the use of heminested
real-time PCR technology rather than simple real-time PCR.
A similar sensitivity of 90.2% has been reported elsewhere for
AFB smear-negative respiratory samples (most of the non-
respiratory specimens tested in this study were also smear
negative) using the Xpert MTB assay kit (3). Moreover, as
other authors have suggested, the Xpert MTB/RIF assay sys-
tem appears to be less susceptible than other PCR-based meth-
ods to cross-contamination by amplicons generated by other
methods that might give rise to false positives (2).
Both assay techniques tested here were rapid, providing
results in less than 2 h, and required little handling by labora-
TABLE 1. Statistical results for the performances of the two molecular assay techniques evaluated, relative to reference culture resultsa
Assay No. of positive tests/no. of positive samples(% sensitivity; 95% CI)
No. of negative tests/no. of negative samples
(% specificity; 95% CI) % PPV (95% CI) % NPV (95% CI)
Xpert MTB/RIF 39/41 (95; 87–100) 299/299 (100; 99–100) 100 (98–100) 99 (98–100)
Cobas TaqMan MTB 32/41 (78; 64–91) 294/299 (98; 96–99) 86 (74–98) 97 (94–99)
a Total of 340 samples tested.
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tory staff. This is particularly true of the Xpert MTB/RIF kit,
in which extraction, amplification, and detection take place
within a single-use multichambered cartridge, thus ensuring
minimal sample contamination. Since manual extraction is rec-
ommended when using the Cobas TaqMan MTB assay kit,
there is clearly a greater scope for contamination. The Xpert
MTB/RIF system allows sample processing to be carried out
on demand, sample by sample, rather than having to set up a
set of samples (usually at least 10 samples and two controls) in
order not to waste reagents, as generally happens with the
Cobas TaqMan MTB kit.
Both molecular techniques represent an important contri-
bution to the detection of M. tuberculosis, since they can pro-
vide results in a matter of hours, whereas the reference culture
method takes days. Real-time PCR techniques afford greater
sensitivity and specificity and a much-reduced response time,
as well as enabling visualization of amplification curves.
One limitation of these techniques is that, in detecting M.
tuberculosis DNA, they cannot distinguish between viable and
nonviable microorganisms. For that reason, although these
assays are semiquantitative, they should not be used for mon-
itoring patient progress or treatment efficacy.
Molecular techniques, of course, are considerably more ex-
pensive than traditional culture methods using either liquid or
solid medium, but they represent a major contribution to the
modern-day detection of tuberculosis.
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